Actovegin rr d / in. 40mg/1ml in amp. 5ml in cont. cell pack. №5х1

Name:
Actovegin rr d / in. 40mg/1ml in amp. 5ml in cont. cell pack. No. 5×1
Description:
Transparent, yellowish solution, practically free from particles. The main active ingredient of actovegin concentrate Form of release solution for injection Dosage 40 mg / 1 ml Pharmacological properties Pharmacodynamics Deproteinized hemoderivative of calf blood causes an increase in the energy metabolism of cells, which is not organ-specific. This activity is confirmed by the results of measurements of increased accumulation and increased utilization of glucose and oxygen. The total effect of these processes leads to an increase in ATP metabolism and, accordingly, to an increase in the energy supply of the cell. In deficient conditions with impaired normal functioning of energy metabolism (hypoxia, substrate deficiency) and in conditions with increased energy needs (repair, regeneration), Actovegin® activates energy-dependent processes of functional metabolism and conservation metabolism. As a secondary effect, there is an increase in blood supply. Pharmacokinetics With the help of chemical-analytical methods, it is impossible to study the pharmacokinetic parameters of Actovegin®, such as absorption, distribution and excretion, since its active ingredients are physiological components that are normally present in the body. The study of various parameters in animal experiments and in clinical studies has shown that the effect of Actovegin® begins to appear no later than 30 minutes after application. The maximum effect after parenteral administration or oral administration is achieved after 3 hours (2-6 hours). Indications for use metabolic and vascular disorders of the brain (including dementia); peripheral (arterial and venous) vascular disorders and their consequences (arterial angiopathy, venous ulcers of the lower extremities), including diabetic polyneuropathy. point up! Allow the solution to drain from the top of the ampoule by lightly tapping the ampoule and shaking it. Take the ampoule pointing the colored dot up! Break off the top of the ampoule as shown. The solution for injection has a slightly yellowish color. The color intensity of the drug from different series may vary due to the raw materials used. Color does not affect the efficacy and tolerability of the drug. Actovegin® solution for injection can be administered intravenously (IV), intramuscularly (IM) or intra-arterially (IV), and it can also be added to infusion solutions. When administered as an infusion, 10-50 ml of the drug is added to 200-300 ml of the stock solution (isotonic sodium chloride solution or 5% glucose solution). Rate of infusion: approximately 2 ml/min. When administered as an infusion, general contraindications to infusion therapy should be taken into account, such as decompensated heart failure, pulmonary edema, oliguria, anuria, and hyperhydration. Dosage depending on specific indications Metabolic and vascular disorders of the brain: from 5 to 25 ml (200-1000 mg per day) intravenously daily for two weeks, followed by the transition to a tablet form. Metabolic and vascular disorders of the brain, such as ischemic stroke: 20-50 ml (800-2000 mg) in 200-300 ml of 0.9% sodium chloride solution or 5% dextrose solution, intravenously drip daily for 1 week, then 10-20 ml (400-800 mg) intravenously drip – 2 weeks, followed by the transition to the tablet form. Peripheral (arterial and venous) vascular disorders and their consequences: 20-30 ml (800-1000 mg) of the drug in 200 ml of 0.9% sodium chloride solution or 5% dextrose solution intra-arterially or intravenously daily; the duration of treatment is 4 weeks. Venous ulcers of the lower extremities: 10 ml (400 mg) intravenously or 5 ml intramuscularly daily or 3-4 times a week, depending on the healing process. Diabetic polyneuropathy: 50 ml (2000 mg) per day intravenously for 3 weeks, followed by the transition to the tablet form – 2-3 tablets 3 times a day for at least 4-5 months. The duration of the course of treatment is determined individually according to the symptoms and severity of the disease. Use during pregnancy and lactation Use during pregnancy During pregnancy, Actovegin® should be used only if the therapeutic benefit outweighs the potential risk to the fetus. Use during breastfeeding During breastfeeding, Actovegin® should be used only if the therapeutic benefit outweighs the potential risk to the child. Precautions For parenteral administration of Actovegin®, sterility must be observed during manipulations. Actovegin® is intended for single use as it does not contain preservative additives. Opened ampoules and the prepared solution should be used immediately. Unused drug and used consumable must be disposed of in accordance with local regulations. When mixing the contents of Actovegin® ampoules with other solutions for injection or infusion, physical and chemical incompatibility, as well as interaction between active substances, cannot be excluded, even if the solution remains clear. As a result, it is unacceptable to mix Actovegin® with other drugs, with the exception of those mentioned in the section “General Dosing Instructions”. With the / m use of Actovegin® should be administered slowly, no more than 5 ml, since the solution is hypertonic. Parenteral administration of Actovegin® should be carried out under medical supervision in the presence of appropriate means for the treatment of allergic reactions. Due to the possibility of anaphylactic reactions, a test infusion/injection (hypersensitivity test) is recommended before starting therapy. Do not use a solution that is cloudy or with visible solid particles. It is a source of sodium, which should be considered when prescribing to patients on a controlled sodium diet. In the presence of electrolyte disturbances (such as hyperchloremia and hypernatremia), they should be adequately corrected. Interactions with other drugs are not known. Contraindications Allergy to Actovegin® or similar drugs or excipients. Composition 1 ampoule (2 ml) contains actovegin concentrate as an active substance (in terms of dry deproteinized calf blood hemoderivat) – 80 mg, containing sodium chloride – 53.6 mg; excipient: water for injection – up to 2 ml. 1 ampoule (5 ml) contains actovegin concentrate as an active substance (in terms of dry deproteinized calf blood hemoderivat) – 200 mg, containing sodium chloride – 134.0 mg; excipient: water for injection – up to 5 ml. 1 ampoule (10 ml) contains actovegin concentrate as an active substance (in terms of dry deproteinized calf blood hemoderivat) – 400 mg, containing sodium chloride – 268.0 mg; excipient: water for injection – up to 10 ml. Overdosage There is no information regarding overdose of Actovegin®. Based on the available pharmacological data, no additional adverse effects are expected. Side effect In the information below, undesirable effects are evaluated according to the following classification of the frequency of their occurrence: Very common? 1/10 Frequent from ? 1/100 to < 1/10 Uncommon from ? 1/1000 to < 1/100 Rare from ? 1/10,000 to < 1/1,000 Very rare < 10,000 Frequency not established (frequency cannot be estimated from the available data) Immune system disorders Rare: allergic reactions (drug fever, symptoms of shock). Skin and subcutaneous tissue disorders Rare: urticaria, flushing of the face. Storage conditions Store in a place protected from light at a temperature not exceeding 25 ° C. Keep out of the reach of children! Buy Actovegin solution for injection. 40mg/1ml in amp. 5ml in cont. cell pack. No. 5x1 Price for Actovegin rr d / in. 40mg/1ml in amp. 5ml in cont. cell pack. No. 5x1 Instructions for use for Actovegin rr d / in. 40mg/1ml in amp. 5ml in cont. cell pack. №5х1